January 27th- Mantle Cell Lymphoma in 2026: From Chemo-Immunotherapy to Precision, Chemo-Free Strategies CME Congresses . January 27th- Mantle Cell Lymphoma in 2026: From Chemo-Immunotherapy to Precision, Chemo-Free Strategies January 26th- From Ibrutinib to Zanubrutinib in Waldenström Macroglobulinemia: Is Switching Safe- and Does It Matter? CME Congresses . January 26th- From Ibrutinib to Zanubrutinib in Waldenström Macroglobulinemia: Is Switching Safe- and Does It Matter? January 21st- Microbiota and GVHD: From Unmet Need to a New Therapeutic Paradigm CME Congresses . January 21st- Microbiota and GVHD: From Unmet Need to a New Therapeutic Paradigm January 19th- Luspatercept in Lower-Risk MDS- where do we stand CME Congresses . January 19th- Luspatercept in Lower-Risk MDS- where do we stand January 12th- “Genomically Smoldering” Myeloma Really Smoldering? CME Congresses . January 12th- “Genomically Smoldering” Myeloma Really Smoldering? January 5th- Linvoseltamab in relapsed refractory multiple myeloma: Durable Responses and Real-World Relevance CME Congresses . January 5th- Linvoseltamab in relapsed refractory multiple myeloma: Durable Responses and Real-World Relevance December 31st- Post-Transplant Cyclophosphamide in HLA-Matched Peripheral Blood Transplantation CME Congresses . December 31st- Post-Transplant Cyclophosphamide in HLA-Matched Peripheral Blood Transplantation December 29th- Dr. Richard Dillon and Dr. Jad Othman- Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML CME Congresses . December 29th- Dr. Richard Dillon and Dr. Jad Othman- Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML December 23rd- PRECISION-T: Are We Entering a New Era of GVHD Prophylaxis? CME Congresses . December 23rd- PRECISION-T: Are We Entering a New Era of GVHD Prophylaxis? December 19th- BEYOND the Horizon: Long-Term Luspatercept Data in non–transfusion-dependent β-thalassemia CME Congresses . December 19th- BEYOND the Horizon: Long-Term Luspatercept Data in non–transfusion-dependent β-thalassemia Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18
